Q-omics provides the consensus-scored SNORD66 profile across patient tissues and cancer cell-line models. SNORD66 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, SNORD66 is differentially expressed in 3, with the highest sampling consensus in LUAD. Additionally, SNORD66 RNA expression shows 7,109 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight COAD, LUAD, and LSCC as cancer lineages where SNORD66 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNORD66 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNORD66 survival associations across molecular data types. SNORD66 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNORD66 RNA expression–survival associations across cancer types. High SNORD66 expression shows unfavorable associations in COAD, LUAD, OV, BRCA, MESO and UVM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for SNORD66 RNA expression.
This table summarizes SNORD66 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SNORD66. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNORD66 shows higher tumor expression in LUAD, COAD and KIRC. The LUAD box plot shows higher SNORD66 RNA expression in tumor versus normal tissue (log2 FC = +0.259, t-test p = .023).
This table shows molecular features associated with SNORD66 in patient tissues and cancer cell lines. In patient samples, SNORD66 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
